NervGen Pharma Corp. 即将完成1B/2a期CONNECT-SCI亚急性四肢瘫患者入组并揭盲数据

美股速递
Apr 07

NervGen Pharma Corp. 宣布,其针对亚急性脊髓损伤导致四肢瘫患者的1B/2a期CONNECT-SCI临床试验即将完成患者入组工作。随着这一关键节点的达成,公司下一步将着手进行数据揭盲,以评估其候选药物的有效性与安全性。这一进展标志着该药物在神经修复领域的临床开发迈出了重要一步。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10